Terms: = Breast cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Clinical Outcome
5 results:
1. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract] [Full Text] [Related]
2. An insight into clinical outcome of XPG polymorphisms in breast cancer.
Malik SS; Mubarik S; Masood N; Khadim MT
Mol Biol Rep; 2018 Dec; 45(6):2369-2375. PubMed ID: 30255276
[TBL] [Abstract] [Full Text] [Related]
3. Calpain system protein expression in basal-like and triple-negative invasive breast cancer.
Storr SJ; Lee KW; Woolston CM; Safuan S; Green AR; Macmillan RD; Benhasouna A; Parr T; Ellis IO; Martin SG
Ann Oncol; 2012 Sep; 23(9):2289-2296. PubMed ID: 22745213
[TBL] [Abstract] [Full Text] [Related]
4. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
Ibrahim SA; Yip GW; Stock C; Pan JW; Neubauer C; Poeter M; Pupjalis D; Koo CY; Kelsch R; Schüle R; Rescher U; Kiesel L; Götte M
Int J Cancer; 2012 Sep; 131(6):E884-96. PubMed ID: 22573479
[TBL] [Abstract] [Full Text] [Related]
5. RACK1: A superior independent predictor for poor clinical outcome in breast cancer.
Cao XX; Xu JD; Liu XL; Xu JW; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Int J Cancer; 2010 Sep; 127(5):1172-9. PubMed ID: 20020495
[TBL] [Abstract] [Full Text] [Related]
